Symmetry Partners LLC Purchases New Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

Symmetry Partners LLC purchased a new stake in Axon Enterprise, Inc. (NASDAQ:AXONFree Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 747 shares of the biotechnology company’s stock, valued at approximately $234,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. HB Wealth Management LLC lifted its holdings in Axon Enterprise by 3.9% in the fourth quarter. HB Wealth Management LLC now owns 1,139 shares of the biotechnology company’s stock worth $294,000 after acquiring an additional 43 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its holdings in shares of Axon Enterprise by 1.1% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 3,997 shares of the biotechnology company’s stock valued at $1,033,000 after buying an additional 43 shares during the last quarter. UMB Bank n.a. boosted its position in shares of Axon Enterprise by 11.0% during the fourth quarter. UMB Bank n.a. now owns 444 shares of the biotechnology company’s stock worth $115,000 after buying an additional 44 shares during the period. Lindbrook Capital LLC grew its holdings in Axon Enterprise by 43.3% in the 4th quarter. Lindbrook Capital LLC now owns 172 shares of the biotechnology company’s stock worth $44,000 after buying an additional 52 shares in the last quarter. Finally, NBC Securities Inc. grew its holdings in Axon Enterprise by 1.4% in the 4th quarter. NBC Securities Inc. now owns 3,843 shares of the biotechnology company’s stock worth $992,000 after buying an additional 53 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON traded down $3.65 on Tuesday, reaching $293.52. 361,731 shares of the company traded hands, compared to its average volume of 489,732. Axon Enterprise, Inc. has a fifty-two week low of $175.37 and a fifty-two week high of $329.87. The company’s 50 day moving average is $297.59 and its 200-day moving average is $281.67. The stock has a market capitalization of $22.15 billion, a PE ratio of 86.89 and a beta of 0.91. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.91 and a quick ratio of 2.55.

Axon Enterprise (NASDAQ:AXONGet Free Report) last announced its quarterly earnings data on Friday, May 10th. The biotechnology company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.20. The company had revenue of $460.74 million during the quarter, compared to the consensus estimate of $441.57 million. Axon Enterprise had a return on equity of 11.71% and a net margin of 15.60%. The company’s quarterly revenue was up 34.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.51 EPS. As a group, analysts anticipate that Axon Enterprise, Inc. will post 2.35 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Julie A. Cullivan sold 993 shares of the stock in a transaction on Friday, May 31st. The stock was sold at an average price of $281.72, for a total value of $279,747.96. Following the completion of the sale, the director now owns 4,553 shares in the company, valued at $1,282,671.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Julie A. Cullivan sold 478 shares of the stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $286.04, for a total transaction of $136,727.12. Following the completion of the sale, the director now directly owns 5,546 shares in the company, valued at $1,586,377.84. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Julie A. Cullivan sold 993 shares of the stock in a transaction on Friday, May 31st. The stock was sold at an average price of $281.72, for a total value of $279,747.96. Following the sale, the director now owns 4,553 shares of the company’s stock, valued at $1,282,671.16. The disclosure for this sale can be found here. Insiders sold 89,447 shares of company stock worth $27,684,677 over the last quarter. Corporate insiders own 5.70% of the company’s stock.

Analyst Upgrades and Downgrades

AXON has been the subject of a number of recent analyst reports. Robert W. Baird increased their price objective on Axon Enterprise from $260.00 to $300.00 and gave the stock an “outperform” rating in a report on Thursday, February 22nd. JMP Securities reissued a “market outperform” rating and issued a $375.00 price objective on shares of Axon Enterprise in a report on Tuesday, May 7th. Morgan Stanley increased their price objective on Axon Enterprise from $285.00 to $310.00 and gave the stock an “equal weight” rating in a report on Friday, April 26th. StockNews.com lowered Axon Enterprise from a “buy” rating to a “hold” rating in a report on Thursday, March 14th. Finally, Barclays increased their price target on Axon Enterprise from $308.00 to $381.00 and gave the company an “overweight” rating in a research note on Wednesday, May 8th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $335.27.

View Our Latest Report on AXON

About Axon Enterprise

(Free Report)

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

See Also

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXONFree Report).

Institutional Ownership by Quarter for Axon Enterprise (NASDAQ:AXON)

Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.